Sanofi has out-licensed its KY1066 antibody to New Haven, CT-based Rallybio who has redubbed it RLYB331. The deal saw Rallybio make an upfront cash payment of $3 million to Sanofi in addition to promising development and commercial milestones and mid to high single-digit royalties on net sales.
Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.
Nan Fung Life Sciences
We have an important job to do. Find your role.
Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
San Diego, California, [April 28, 2022] – Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker,
Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers
Marks key milestone as Evommune’s first clinical program which should allow EVO101 to rapidly advance into Phase 2a